Welcome to our dedicated page for Cronos Group SEC filings (Ticker: CRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a cannabis company that files under two accounting regimes can feel like navigating a greenhouse at night. Cronos Group’s SEC reports weave together fair-value changes in biological assets, strategic deals with Altria, and shifting international regulations—details easy to miss in a 300-page 10-K. That’s exactly why investors search for “Cronos Group SEC filings explained simply” and “Cronos Group annual report 10-K simplified.” Our platform turns that complexity into clarity.
Stock Titan’s AI reads every Cronos Group quarterly earnings report 10-Q filing, flags where revenue swings tie back to harvest yields, and connects Form 8-K material events to market-moving announcements. Need real-time alerts for Cronos Group insider trading Form 4 transactions? We deliver them seconds after EDGAR posts. Prefer narrative? Our summaries translate cannabis yield per gram and R&D spending into plain English so you can focus on decisions, not deciphering footnotes.
Whether you’re comparing segment performance, reviewing Cronos Group proxy statement executive compensation, or monitoring Cronos Group executive stock transactions Form 4, all documents—10-K, 10-Q, 8-K, S-1, SC 13G—sit in one place with AI-powered search. Practical use cases include spotting inventory write-downs before earnings, benchmarking R&D against peers, and tracking Cronos Group Form 4 insider transactions real-time ahead of product launches. Understanding Cronos Group SEC documents with AI means faster insight into cannabis supply dynamics, revenue per gram, and strategic equity deals. Access every detail, updated the moment Cronos files.
Cronos Group Inc. (CRON) filed a Form 4 reporting an equity award to an executive. On November 7, 2025, the SVP, Head of Cronos Israel, received 60,728 restricted stock units (RSUs), each representing the right to receive one common share. The RSUs vest in three substantially equal annual installments beginning on the first anniversary of the grant date. Following this grant, 138,632 derivative securities were beneficially owned directly.
Cronos Group Inc. reported stronger Q3 results. For the three months ended September 30, 2025, net revenue was $36.3 million versus $34.3 million a year ago, led by cannabis flower $26.4 million and extracts $10.0 million. Gross profit rose to $18.3 million from $3.6 million as cost of sales declined.
Operating loss narrowed to $0.5 million from $33.7 million. Total other income was $27.5 million, including a foreign currency gain of $19.8 million and a $4.1 million gain on revaluation of financial instruments, partly offset by a $3.0 million loss on held-for-sale assets and a $4.8 million change in allowance for credit loss on a non-operating loan. Net income attributable to Cronos Group was $26.0 million ($0.07 per diluted share), up from $8.3 million ($0.02) in the prior-year quarter.
Cash and cash equivalents were $784.2 million with $40.0 million of short-term investments. Total assets were $1.178 billion against total liabilities of $46.4 million. Year-to-date, operating activities provided $14.0 million of cash, while investing used $79.3 million and financing used $12.5 million. Canada contributed $23.1 million of quarterly revenue and Israel $11.4 million. Shares outstanding were 382,893,267 as of November 3, 2025.
Cronos Group Inc. furnished an 8-K announcing it issued a press release with financial results for its third quarter ended September 30, 2025.
The press release is attached as Exhibit 99.1. The Item 2.02 information, including Exhibit 99.1, is being furnished, not filed, and is not subject to Section 18 liability or automatically incorporated into other filings. Exhibit 104 provides the cover page Inline XBRL data.
Cronos Group Inc. announced the immediate termination for cause of Lloyd Wilson, who served as Vice President, Controller and Principal Accounting Officer. The company explicitly stated that Wilson's termination was not connected to Cronos Group's financial or operating results, internal controls, or any disagreements regarding the company's financial reporting practices.
James D. Rudyk, a director of Cronos Group Inc. (CRON), acquired 66,079.3 Deferred Share Units (DSUs) on 08/07/2025. Each DSU entitles the reporting person to receive a lump-sum cash payment equal to the fair market value of one common share upon redemption. The filing shows the number of common-share equivalents beneficially owned following the reported transaction as 313,882.29, held directly. The filing also states that vested DSUs are mandatorily redeemed by the company on the first trading day after the reporting person ceases to be a director.
Jason Marc Adler, identified as a director of Cronos Group Inc. (CRON), reported a transaction dated 08/07/2025 in which he acquired 66,079.3 Deferred Share Units (DSUs). The filing shows 66,079.3 DSUs underlying 66,079.3 common shares and reports beneficial ownership of 313,882.29 common shares following the reported transaction, held in a direct ownership form.
The filing explains that upon redemption DSUs pay a lump-sum cash amount equal to the fair market value of Cronos common shares on the redemption date. It also states that vested DSUs are mandatorily redeemed by the company on the first trading day after the reporting person ceases to be a director.
Murray R. Garnick, a director of Cronos Group Inc. (CRON), acquired 66,079.3 deferred share units on 08/07/2025 and reported direct beneficial ownership of 130,734.47 common shares following the transaction.
Deferred share units entitle the holder to a lump sum cash payment equal to the fair market value of Cronos common shares on redemption, and vested units are mandatorily redeemed by the company on the first trading day after the reporting person ceases to be a director.
Cronos Group insider Lloyd A. Wilson filed an initial Form 3 disclosing direct beneficial ownership of 10,500 common shares of Cronos Group Inc. (CRON). The filing identifies the reporting person as an officer with the title VP, Controller and reports no derivative securities. This Form 3 establishes the reporter's baseline public ownership position for future Section 16 disclosures.
On 7 Aug 2025 Cronos Group Inc. (NASDAQ: CRON) filed a Form 8-K disclosing two matters:
- Item 2.02 – Results of Operations: the company issued a press release (Exhibit 99.1) containing its Q2-2025 financial results for the period ended 30 Jun 2025. Specific revenue, earnings or guidance figures are not included in the 8-K body; investors must refer to the attached exhibit for details.
- Item 5.02 – Officer change: effective immediately after the forthcoming Form 10-Q, the Board appointed Lloyd Wilson (53), currently Vice President & Controller, as Principal Accounting Officer. Wilson brings 20+ years of GAAP and SEC-reporting experience, most recently as Corporate Controller at Vital Farms (Nov 2021–Jun 2025) and previously as an auditor at Grant Thornton and KPMG. He replaces James McGinness, who departs the company on the same date.
The filing notes no family relationships, related-party transactions or special arrangements tied to Wilson’s selection. Other sections are routine, and no forward-looking guidance was provided.
FAQ
What is the current stock price of Cronos Group (CRON)?
What is the market cap of Cronos Group (CRON)?
